7 Articles found
Nanostics Inc. Articles
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. ...
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer ...
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics` clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked ...
-
Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients
Edmonton, Alberta - Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient`s disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity ...
-
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ng/mL.
-
Bio-tech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process ...